What is The Progression of Joint Deformity and Disability in Rheumatoid Arthritis Patients with Different Treatment Approaches? : A Systematic Review
Keywords:
Rheumatoid Arthritis, Joint Deformity, Disability, Treatment Approaches, Radiographic Progression, Functional StatusAbstract
Introduction: Rheumatoid Arthritis (RA) is a chronic autoimmune disease leading to progressive joint destruction and disability. Modern management has shifted towards early, aggressive "treat-to-target" strategies to halt disease progression. This systematic review evaluates the progression of joint deformity and disability in RA patients under various treatment approaches. Methods: Following PRISMA guidelines, we systematically reviewed randomized controlled trials from PubMed, Springer, Semantic Scholar, and Google Scholar. We included studies on adult RA patients with at least a 12-month follow-up that assessed joint deformity or functional disability. Nine studies met the inclusion criteria for the final analysis. Results: Early, aggressive treat-to-target strategies resulted in minimal radiographic progression, with some studies showing a complete halt in joint damage over long-term follow-up of up to 10 years. Functional disability, measured by the Health Assessment Questionnaire (HAQ), improved across all pharmacological interventions. Non-pharmacological interventions, like complex rehabilitation, significantly improved functional status, reducing HAQ scores by up to 73.8%, but their effect on radiographic outcomes was not reported. Baseline anti-CCP positivity and high disease activity were predictors of poorer outcomes. Discussion: The evidence confirms that early and sustained pharmacological treatment is crucial for controlling structural damage and preserving function. Combining these treatments with non-pharmacological therapies like targeted exercise provides additional functional benefits. However, a gap remains in understanding the impact of non-pharmacological interventions on long-term joint structure. Conclusion: An integrated approach combining early, aggressive pharmacotherapy with adjunctive non-pharmacological interventions offers the most effective strategy for managing RA. This approach successfully limits joint deformity and improves patient disability and quality of life.
References
Markusse, I., Akdemir, G., Dirven, L., Goekoop-Ruiterman, Y., van Groenendael, J., Han, K. H., Molenaar, T., et al. (2016). “Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment.” Annals of Internal Medicine.
Hetland, M., Østergaard, M., Stengaard-Pedersen, K., Junker, P., Ejbjerg, B., Jacobsen, S., Ellingsen, T., et al. (2018). “Anti-Cyclic Citrullinated Peptide Antibodies, 28-Joint Disease Activity Score, and Magnetic Resonance Imaging Bone Oedema at Baseline Predict 11 Years’ Functional and Radiographic Outcome in Early Rheumatoid Arthritis.” Scandinavian Journal of Rheumatology.
Sundin, U., Aga, A., Skare, Ø., Norberg, L. B., Uhlig, T., Hammer, H., Heijde, D., Kvien, T., Lillegraven, S., & Haavardsholm, E. (2019). “OP0134 ULTRASOUND IN THE MANAGEMENT OF EARLY RHEUMA- TOID ARTHRITIS: MRI OUTCOME DATA FROM THE ARCTIC RANDOMIZED CONTROLLED STRATEGY TRIAL.” Oral Presentations.
McLeod, B. D. (2015). “Combination Intensive DMARD Therapy Is Noninferior to TNF Inhibitors for Reducing Disability in Active RA.” Annals of Internal Medicine.
Krause, D., Mai, A., Timmesfeld, N., Trampisch, U., Klaassen-Mielke, R., Rudolf, H., Baraliakos, X., et al. (2020). “SAT0135 COMPARISON OF THE EFFICACY AND SAFETY OF TWO BRIDGING SCHEDULES OF PREDNISOLONE IN EARLY ACTIVE RHEUMATOID ARTHRITIS (CORRA): A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED TRIAL.” Annals of the Rheumatic Diseases.
Caporali, R., Aletaha, D., Sanmartí, R., Takeuchi, T., Mo, D., Haladyj, E., Zaremba-Pechmann, L., & Taylor, P. (2022). “POS0682 LONG-TERM EFFICACY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO bDMARDs: RESULTS FROM RA-BEYOND FOLLOWING 6.9 YEARS OF TREATMENT.” Annals of the Rheumatic Diseases.
Orlova, E., Karateev, D., & Kochetkov, A. (2018). “FRI0684 Efficiency of Complex Rehabilitation Program in Patients with Rheumatoid Arthritis Receiving Abatacept.” FRIDAY, 15 JUNE 2018.
Orlova, E., Karateev, D., Denisov, L., Kochetkov, A., & Nasonov, E. (2016). “SAT0617 12-Month Complex Rehabil- itation Program for Rheumatoid Arthritis Patients Receiving Biologic Dmards.”
Orlova, E., Karateev, D., Denisov, L., Kochetkov, A., & Nasonov, E. (2016). “SAT0618 Efficacy of Two Long-Term Exercise Programs in Patients with Early Rheumatoid Arthri- tis: Results of 12-Month Randomized Controlled Trial.”
Published
Issue
Section
License
Copyright (c) 2025 Billy Jonathan, Veronica Winda Soesanto, Chaira Sultana Mazaya (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors publishing here keep copyright but grant the journal first publication rights, under a Creative Commons Attribution-NonCommercial 4.0 License. They can distribute their work non-exclusively elsewhere with an acknowledgment of its first publication in this journal. Posting the work online before and during submission for earlier and greater citation is encouraged, reflecting Open Access benefits.
